COVID-19/Coronavirus Update

IgG Customer Survey

Survey Customer Survey for SARS-CoV-2 Antibody Test

In our effort to improve your experience with our solutions and services, we request you to fill out a short customer experience survey that should not take more than 10 minutes.

Click here
Front line care worker in scrubs an protective mask

Letter Update on the launch of our SARS-CoV-2 IgG Antibody Test

See how we are helping in the fight against COVID-19 with this letter to our customers in North America from Sarah Moore, Senior VP and General Manager for North America.

Read more

Sample handling precautions and instrument maintenance

We know that our partners use our instruments to test specimens that contain infectious or potentially infectious pathogens. The safety of your staff—and our associates—is very important to us.

There are no additional decontamination procedures recommended for the Beckman Coulter in vitro diagnostic instruments your laboratory uses to test specimens obtained from suspected or confirmed cases of COVID-19. Follow routine maintenance and cleaning procedures specified in your system documentation. Beckman Coulter recommends using bleach with your instrument only as directed in your instrument Instructions for Use (IFU).

Always follow the policies and procedures established by your institution’s infection control and risk management departments. The proper use of personal protective equipment (PPE) and universal laboratory biosafety precautions will minimize the exposure of laboratory personnel to potentially infectious pathogens.

Supply continuity and planning

While it is not possible to forecast the impact of geopolitical events on future supply, we want to assure you that we are actively monitoring and managing our business continuity plan so that critical products are available to support the needs of our customers, healthcare providers and patients.

We have clear visibility into our supply chain to mitigate the impact on our customers, and we are following direction from international health organizations and local governments as well as Danaher and Beckman Coulter safety protocols.

Currently, all Beckman Coulter production sites are operational. While we have manufacturing facilities and suppliers in impacted regions, we are prepared with solid inventory reserves and strong supplier relationships, allowing us to avoid supply outages. Additionally, we are continuing to leverage our established partnerships in the logistics community to move freight around the globe.

As the situation progresses, we will monitor and provide any necessary updates to ensure consistent support.

If you are a Beckman Coulter customer and require additional details on supply continuity, please contact your local sales representative.

Steps other Danaher companies are taking in the fight against COVID-19

Beckman Coulter is proud to be part of Danaher which is made up of a collection of the world’s leading diagnostic and Life Science companies, including Cepheid and Integrated DNA Technologies (IDT).

The global Cepheid team is mobilizing quickly to deliver a world-class, point-of-care test for the rapid qualitative detection of the 2019 novel coronavirus. “An accurate test performed close to the patient with a rapid turnaround time will deliver time-critical results to help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on healthcare facilities. By leveraging the design principles of our current Xpert® Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and future pandemic coronavirus strains, we are developing a test that can be applied in multiple settings where actionable patient management information is needed quickly.” David Persing, MD, Ph.D. Cepheid’s Chief Medical and Technology Officer.

To learn more about Cepheid’s SARS-CoV-2 test development, including news, FAQ’s and expected product details, visit Cepheid’s dedicated COVID-19 information page.

IDT was the first company in the nation to have its primer and probe kits approved by the US Centers for Disease Control and Prevention (CDC) for use as a key component of the CDC Emergency Use Authorization (EUA) test protocol for the diagnosis and detection of COVID-19. IDT has achieved large-scale manufacturing of this key component, which assists in DNA analysis of patient samples. IDT has manufactured, and CDC has qualified, primer and probe kits sufficient to enable over 5 million tests per week to be conducted pursuant to the CDC EUA testing protocol. IDT will also continue to supply primer and probe kits to research laboratories which may assist them in the development of a COVID-19 vaccine.

To learn more about IDT's role in the fight against COVID-19, visit IDT’s dedicated information page.

Event and conference participation

Due to COVID-19, we have made the decision to cancel or modify our participation in upcoming tradeshows and industry events until further notice. To keep up to date with the latest tradeshow and event news, please visit our events page.

Beckman Coulter site visitor guidance

We are following direction from international health organizations, local governments, as well as Beckman Coulter and Danaher safety protocols to minimize exposure. If you (or someone you have been in close contact with) are exhibiting symptoms of respiratory tract infection or have visited any of the destinations identified by the CDC as being at risk of community spread of coronavirus (China, Hong Kong, Iran, Italy, Japan, Singapore, South Korea, Taiwan, Thailand China, and the Republic of Korea) within the last 14 days please refrain from visiting the Beckman Coulter offices.

The CDC also recommends that if you develop a fever or respiratory symptoms consistent with COVID-19, you should immediately self-quarantine and notify your healthcare provider or local public health authorities.